Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Ataraxis AI›
Products & Services
AddedJun 26, 2026
UpdatedJun 26, 2026
Ataraxis Breast

Ataraxis AI› offers Ataraxis Breast

Product
Currently Offered

AI-powered clinical tests for breast cancer treatment selection, integrating pathology and clinical data to predict recurrence risk and therapy response.

Loading
Overview

Ataraxis Breast is a suite of AI-powered clinical tests designed to personalize breast cancer care. Built on multimodal artificial intelligence, the platform integrates digitized H&E pathology slides with clinical data to predict recurrence risk, treatment benefit, and therapy response.

The suite includes Ataraxis Breast RISK (prognostic recurrence prediction), CTX (predictive chemotherapy benefit), and NEO (neoadjuvant therapy response), supporting decision-making across all major breast cancer subtypes. Tests are delivered through a CLIA-certified laboratory with one-day turnaround.

Ataraxis Breast - Classification

Industry
  • AI
  • Healthcare Technology
Ownership
  • Private
Technology
  • AI
Model
  • Biotechnology Company
Revenue
  • B2B
Customer
  • Healthcare Providers
Tags
  • Precision Oncology

Ataraxis Breast - Direct Competitors

  • Tempus

    Tempus logo

    Genomic Profiling for Precision Oncology

    tempus.com

AttributeAtaraxis BreastGenomic Profiling for Precision Oncology
ProviderAtaraxis AIataraxis.ai$20.4M raised · Series ATempustempus.com$1.3B raised · Late Stage Private
Founded20232015
Sells ToHealthcare Providers—
Pricing ModelB2BSoftware
OwnershipPrivateEquity, Venture Capital
Ataraxis Breast

Provider Ataraxis AIataraxis.ai$20.4M raised · Series A

Founded 2023

Sells To Healthcare Providers

Pricing Model B2B

Ownership Private

Genomic Profiling for Precision Oncology

Provider Tempustempus.com$1.3B raised · Late Stage Private

Founded 2015

Sells To —

Pricing Model Software

Ownership Equity, Venture Capital

Ataraxis Breast - Similar Products & Services

  • Healthcare Data and Analytics Platform logo

    Healthcare Data and Analytics Platform

    fuzehealth.com